Novo Nordisk abandons inflammatory disease
This article was originally published in Scrip
Executive Summary
Novo Nordisk is dropping all its R&D activities into inflammatory disorders following the discontinuation of its lead anti-inflammatory product, anti-IL-20 for the treatment of rheumatoid arthritis, which it announced last month.